α-Synuclein Aggregation in Treatment of Parkinson's Disease
Por um escritor misterioso
Descrição
Parkinson’s disease, the second most common neurodegenerative disorder worldwide, is characterized by the accumulation of protein deposits in the dopaminergic neurons. These deposits are primarily composed of aggregated forms of α-Synuclein (α-Syn). PD is a complex pathology initially associated with motor deficiencies, as a result of an acute neuronal loss in substantia nigra pars compacta (SNc), with a significant dopaminergic (DA) impairment.
Calcipotriol inhibits α‐synuclein aggregation in SH‐SY5Y neuroblastoma cells by a Calbindin‐D28k‐dependent mechanism - Rcom‐H'cheo‐Gauthier - 2017 - Journal of Neurochemistry - Wiley Online Library
Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms of Parkinson's Disease - Pharma Excipients
Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing mice - Aniszewska - 2022 - Brain and Behavior - Wiley Online Library
Small soluble α-synuclein aggregates are the toxic species in Parkinson's disease
Tissue transglutaminase-induced aggregation of α-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies
α-Synuclein aggregation process (α-syn, principal constituent of
Frontiers The Role of Lipids in the Initiation of α-Synuclein Misfolding
Alpha Synuclein – The Science of Parkinson's
Targeting α-synuclein aggregation with immunotherapy: a promising therapeutic approach for Parkinson's disease
Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
de
por adulto (o preço varia de acordo com o tamanho do grupo)
